Table 1.
MiRNA related with MDSC in tumor progression.
| MiRNA | Status | Target | MiRNA’s regulating in TAM | Impact on tumor progression |
|---|---|---|---|---|
| MiR-155 | Increased | FGF2 | Enhance suppressive function | Suppress the cell viability, migration and invasion (32) |
| MiR-98 | Increased | IL-10 | Inhibit the function of TAM | Suppress migration and invasion of hepatocellular carcinoma cells (28) |
| Let-7a | Increased | STAT3 NF-κB | Suppress macrophage infiltrations and malignant phenotype | Decrease tumor growth (33) |
| MiR-30a | Increased | Twist1 Vimentin | Inhibit the function of TAM | Promote metastatic potential of bladder cancer (34) |
| MiR-25- 3p MiR-130b-3p MiR-425-5p | Increased | PTEN | Induce M2 polarization | Promote cancer metastasis (35) |
| MiR-125a | Increased | HIF-1α IRF4 | Increase phagocytic activation | Repress tumor growth (36) |
| MiR-145 | Increased | histone deacetylase 11 | Polarize macrophage-like cells into the M2-like phenotype | Enlarge the tumor volumes (20) |
| MiR-142-3p | Increased | RAC1 | Propofol stimulates TAM to secrete miR-142-3p | Inhibit HCC cell invasion (37) |
| MiR-21 | Increased | PI3K/ AKT | Enhance the function of M2 TAM | Suppress cell apoptosis and confer cisplatin resistance in gastric cancer (38) |
| MiR-100 | Increased | mTOR | Maintain the phenotype of TAMs | Promote tumor metastasis (18) |
| MiR-125b | Increased | CSF1/CX3CL1 | Decrease the abundance of TAM | Alleviate the tumor growth (39) |
| MiR-1246 | Increased | Reprogram macrophages to a tumor supportive and anti-inflammatory state | Promote colon cancer progression and metastasis (22) | |
| MiR-375 | Increased | TNS3 PXN | Enhance macrophage migration and infiltration | Develop a tumor-promoting microenvironment (19) |
| MiR-720 | Increased | GATA3 | Suppress M2 macrophage polarization | Inhibit migration of breast carcinomas (40) |
| MiR-221-3p | Increased | CDKN1B | Enhance function of TAM | Contribute to the proliferation and G1/S transition of epithelial ovarian cancers (41) |
| MiR-125b-5p | Increased | LIPA | Induce a tumor-promoting TAM phenotype | Promote tumor development (42) |
| MiR‐30c | Increased | REDD1 | Promote M1 macrophage differentiation | (43) |
| MiR‐362‐3p | Increased | CD82 | M2 macrophages mediate overexpression of miR‐362‐3p | Promote epithelial‐mesenchymal transition in hepatocellular carcinoma cells (30) |
| MiR-155 | Decreased | C/EBPb | Promote tumor-activated monocytes to produce cytokine | (44) |
| MiR-34a | Decreased | VEGF | TAM release TGF-β to downregulate miR-34a | Improve the proliferation and invasion of colorectal cancer (27) |
| MiR- 4319 | Decreased | NECAB3 | Promote M2 macrophage polarization | Promote Non-small cell lung cancer progression (45) |
| MiR-21 | Increased | SNAI1 MRC1 | Suppress M1 markers and enhance M2 markers | Promote tumor angiogenesis and growth (21) |
| MiR-101 | Increased | DUSP1 | Regulate macrophage to innate immune responses | Promote hepatocarcinoma growth and metastases (46) |
| MiR-222-3p | Increased | SOCS3 | Induce polarization of the M2 phenotype | As a biomarker of epithelial ovarian cancer (47) |
| MiR-106b-5p | Increased | IRF1/IFN-β | Promote M2 polarization | Enhance glioma growth (48) |
| MiR-17 MiR-20a | HIF-2a | Enhance proangiogenic | Contribute to the angiogenic process within tumors (29) | |
| MiR-30e* | Decreased | Bmi1 | Enhance the regulation mediated by TAM | Promote tumor growth, invasion, and metastasis of gastrointestinal cancer (49) |
| MiR-146a MiR-222 | Decreased | NF-κB p50 subunit | Promote the phenotype molecules of M2 macrophage Enhance TAM chemotaxis | Promote tumor growth (50) |
| MiR let-7b | Decreased | Modulate macrophage polarization | Reduce angiogenesis and prostate carcinoma (51) | |
| MiR-125a/b | Decreased | CD90 | Enhance the function of TAM | Promote HCC cell proliferation and stem cell properties (31) |